Walter V. Klemp's most recent trade in Moleculin Biotech Inc was a trade of 2,027,025 Series E Warrants done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Jun 2025 | 2,027,025 | 2,409,481 | - | - | Series E Warrants | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 20 Jun 2025 | 675,675 | 743,607 (1%) | 1% | 0.4 | 250,000 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 8,990 | 70,122 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 8,990 | 382,456 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 3,750 | 62,046 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 3,750 | 391,446 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.27 per share. | 20 Jun 2025 | 2,190 | 67,932 (0%) | 0% | 0.3 | 585 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.27 per share. | 20 Jun 2025 | 914 | 61,132 (0%) | 0% | 0.3 | 244 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 1,667 | 58,702 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 1,667 | 370,075 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.68 per share. | 16 Jun 2025 | 406 | 58,296 (0%) | 0% | 0.7 | 278 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 115,000 | 328,152 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 100,000 | 213,152 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 43,590 | 371,742 | - | - | Performance Based Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2024 | 982 | 57,275 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2024 | 982 | 113,152 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.57 per share. | 02 Jul 2024 | 240 | 57,035 (0%) | 0% | 3.6 | 857 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2024 | 8,990 | 114,134 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2024 | 8,990 | 58,483 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.74 per share. | 22 Jun 2024 | 2,190 | 56,293 (0%) | 0% | 3.7 | 8,191 | Common Stock |
| Autonomix Medical Inc. | Walter V. Klemp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 175,452 | 200,452 | - | - | Option (Right to buy) | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2024 | 3,750 | 123,124 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2024 | 3,750 | 50,407 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.78 per share. | 20 Jun 2024 | 914 | 49,493 (0%) | 0% | 3.8 | 3,455 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 1,667 | 47,063 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 1,667 | 126,874 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.14 per share. | 16 Jun 2024 | 406 | 46,657 (0%) | 0% | 4.1 | 1,681 | Common Stock |
| Moleculin Biotech Inc | Klemp Walter V. | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.69 per share. | 26 Dec 2023 | 188,404 | 680,880 (1%) | 0% | 0.7 | 129,999 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 13,204 | 1,928,145 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 13,204 | 495,692 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.59 per share. | 11 Jul 2023 | 3,216 | 492,476 (0%) | 0% | 0.6 | 1,898 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2023 | 14,717 | 1,941,349 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2023 | 14,717 | 486,072 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.58 per share. | 02 Jul 2023 | 3,584 | 482,488 (0%) | 0% | 0.6 | 2,074 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 539,375 | 1,956,066 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 400,000 | 1,416,691 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 56,250 | 485,052 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 56,250 | 1,016,691 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.57 per share. | 20 Jun 2023 | 13,697 | 471,355 (0%) | 0% | 0.6 | 7,807 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 25,000 | 1,072,941 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 25,000 | 434,890 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.57 per share. | 16 Jun 2023 | 6,088 | 428,802 (0%) | 0% | 0.6 | 3,470 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 1.28 per share. | 25 Nov 2022 | 45,000 | 409,890 (0%) | 0% | 1.3 | 57,632 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 1.15 per share. | 21 Nov 2022 | 22,500 | 364,890 (0%) | 0% | 1.1 | 25,866 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2022 | 13,205 | 1,369,941 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2022 | 13,204 | 235,650 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.68 per share. | 11 Jul 2022 | 3,215 | 232,435 (0%) | 0% | 1.7 | 5,401 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2022 | 14,717 | 226,030 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2022 | 14,717 | 1,383,145 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 02 Jul 2022 | 3,584 | 222,446 (0%) | 0% | 1.5 | 5,268 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 362,000 | 1,397,862 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2022 | 360,000 | 1,035,862 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 25,000 | 675,862 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 25,000 | 217,401 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.33 per share. | 16 Jun 2022 | 6,088 | 211,313 (0%) | 0% | 1.3 | 8,097 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2021 | 13,205 | 700,862 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2021 | 13,205 | 195,616 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 11 Jul 2021 | 3,215 | 192,401 (0%) | 0% | 3.6 | 11,445 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 14,718 | 185,995 (0%) | 0% | - | Common Stock | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 14,718 | 717,651 | - | - | Restricted Stock Units | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 02 Jul 2021 | 3,584 | 182,411 (0%) | 0% | 3.6 | 12,759 | Common Stock |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 223,635 | 628,785 | - | - | Stock option (right to buy) | |
| Moleculin Biotech Inc | Walter V. Klemp | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 100,000 | 728,785 | - | - | Restricted Stock Units |